Progress in Cardiovascular Diseases
Volume 52, Issue 4 , Pages 347-361 , January 2010

Amyloid Heart Disease

  • Rodney H. Falk

      Affiliations

    • Harvard Vanguard Medical Associates, Harvard Medical School, Boston, MA, USA
    • Corresponding Author InformationAddress reprint requests to Rodney H. Falk, MD, Harvard Vanguard Medical Associates 133, Brookline Ave, Boston, MA 02215.
    • ,
  • Simon W. Dubrey

      Affiliations

    • Hillingdon Hospital Uxbridge, United Kingdom

References 

  1. Westermark P, Benson MD, Buxbaum JN, et al. A primer of amyloid nomenclature. Amyloid. 2007;14:179–183
  2. Shirahama T, Cohen AS. High-resolution electron microscopic analysis of the amyloid fibril. J Cell Biol. 1967;33:679–708
  3. Westermark P. Aspects on human amyloid forms and their fibril polypeptides. FEBS J. 2005;272:5942–5949
  4. Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol. 2000;130:88–98
  5. Pellikka PA, Holmes DR, Edwards WD, et al. Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement. Arch Intern Med. 1988;148:662–666
  6. Reisinger J, Dubrey SW, Lavalley M, et al. Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement. J Am Coll Cardiol. 1997;30:1046–1051
  7. Dubrey S, Pollak A, Skinner M, et al. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J. 1995;74:541–544
  8. Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation. 2009;119:2490–2497
  9. Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation. 2007;116:2420–2426
  10. Zubkov AY, Rabinstein AA, Dispenzieri A, et al. Primary systemic amyloidosis with ischemic stroke as a presenting complication. Neurology. 2007;69:1136–1141
  11. Koyama J, Davidoff R, Falk RH. Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction. J Am Soc Echocardiogr. 2004;17:36–44
  12. Koyama J, Ray-Sequin PA, Davidoff R, et al. Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol. 2002;89:1067–1071
  13. Koyama J, Ray-Sequin PA, Falk RH. Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation. 2003;107:2446–2452
  14. Ogiwara F, Koyama J, Ikeda S, et al. Comparison of the strain Doppler echocardiographic features of familial amyloid polyneuropathy (FAP) and light-chain amyloidosis. Am J Cardiol. 2005;95:538–540
  15. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM. 1998;91:141–157
  16. Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol. 1982;49:9–13
  17. Kwong RY, Falk RH. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:122–124
  18. Sparrow P, Amirabadi A, Sussman MS, et al. Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis. J Magn Reson Imaging. 2009;30:942–946
  19. Migrino RQ, Christenson R, Szabo A, et al. Prognostic implication of late gadolinium enhancement on cardiac MRI in light chain (AL) amyloidosis on long term follow up. BMC Med Phys. 2009;9:5
  20. Hosch W, Kristen AV, Libicher M, et al. Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathological findings. Amyloid. 2008;15:196–204
  21. Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186–193
  22. Ruberg FL, Appelbaum E, Davidoff R, et al. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Am J Cardiol. 2009;103:544–549
  23. Maceira AM, Prasad SK, Hawkins PN, et al. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson. 2008;10:54
  24. Kribben A, Witzke O, Hillen U, et al. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. J Am Coll Cardiol. 2009;53:1621–1628
  25. Hazenberg BP, van Rijswijk MH, Piers DA, et al. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med. 2006;119:355.e15–355.e24
  26. Glaudemans AW, Slart RH, Zeebregts CJ, et al. Nuclear imaging in cardiac amyloidosis. Eur J Nucl Med Mol Imaging. 2009;
  27. Giorgadze TA, Shiina N, Baloch ZW, et al. Improved detection of amyloid in fat pad aspiration: an evaluation of Congo red stain by fluorescent microscopy. Diagn Cytopathol. 2004;31:300–306
  28. Ansari-Lari MA, Ali SZ. Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test?. Diagn Cytopathol. 2004;30:178–181
  29. Guy CD, Jones CK. Abdominal fat pad aspiration biopsy for tissue confirmation of systemic amyloidosis: specificity, positive predictive value, and diagnostic pitfalls. Diagn Cytopathol. 2001;24:181–185
  30. Arbustini E, Verga L, Concardi M, et al. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid. 2002;9:108–114
  31. Benson MD, Breall J, Cummings OW, et al. Biochemical characterisation of amyloid by endomyocardial biopsy. Amyloid. 2009;16:9–14
  32. Gertz MA, Grogan M, Kyle RA, et al. Endomyocardial biopsy-proven light chain amyloidosis (AL) without echocardiographic features of infiltrative cardiomyopathy. Am J Cardiol. 1997;80:93–95
  33. Arbustini E, Merlini G, Gavazzi A, et al. Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients. Am Heart J. 1995;130:528–536
  34. Palladini G, Merlini G. Current treatment of AL amyloidosis. Haematologica. 2009;94:1044–1048
  35. Palladini G, Lavatelli F, Russo P, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006;107:3854–3858
  36. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94:1008–1010
  37. Liao RL, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104:1594–1597
  38. Dubrey SW, Cha K, Skinner M, et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart. 1997;78:74–82
  39. Collins AB, Smith RN, Stone JR. Classification of amyloid deposits in diagnostic cardiac specimens by immunofluorescence. Cardiovasc Pathol. 2008;
  40. Stoppini M, Obici L, Lavatelli F, et al. Proteomics in protein misfolding diseases. Clin Chem Lab Med. 2009;47:627–635
  41. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med. 1997;336:1202–1207
  42. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45–59
  43. Nordlinger M, Magnani B, Skinner M, et al. Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure?. Am J Cardiol. 2005;96:982–984
  44. Takemura G, Takatsu Y, Doyama K, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol. 1998;31:754–765
  45. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22:3751–3757
  46. Dispenzieri A, Gertz MA, Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2004;104:1881–1887
  47. Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005;95:535–537
  48. Velazquez-Cecena JL, Lubell DL, Nagajothi N, et al. Syncope from dynamic left ventricular outflow tract obstruction simulating hypertrophic cardiomyopathy in a patient with primary AL-type amyloid heart disease. Tex Heart Inst J. 2009;36:50–54
  49. Dinwoodey DL, Skinner M, Maron MS, et al. Light-chain amyloidosis with echocardiographic features of hypertrophic cardiomyopathy. Am J Cardiol. 2008;101:674–676
  50. Pollak A, Falk RH. Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest. 1993;104:618–620
  51. Al Suwaidi J, Velianou JL, Gertz MA, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med. 1999;131:838–841
  52. Hongo M, Yamamoto H, Kohda T, et al. Comparison of electrocardiographic findings in patients with AL (primary) amyloidosis and in familial amyloid polyneuropathy and anginal pain and their relation to histopathologic findings. Am J Cardiol. 2000;85:849–853
  53. Narang R, Chopra P, Wasir HS. Cardiac amyloidosis presenting as ischemic heart disease. A case report and review of literature. Cardiology. 1993;82:294–300
  54. Mesquita T, Chorao M, Soares I, et al. Primary amyloidosis as a cause of microvascular angina and intermittent claudication. Rev Port Cardiol. 2005;24:1521–1531
  55. Churchill CH, Abril A, Krishna M, et al. Jaw claudication in primary amyloidosis: unusual presentation of a rare disease. J Rheumatol. 2003;30:2283–2286
  56. Schneider BF, Normansell D, Ayers CR, et al. Intermittent claudication as the presenting symptom in primary amyloidosis. Acta Haematol. 1993;90:106–107
  57. Kirsten AV, Schnabel PA, Winter B, et al: High prevalence of amyloid in 150 surgically removed heart valves—a comparison of histological and clinical data reveals correlation to inflammatory conditions. Cardiovasc Pathol. Epub ahead of print, June 2009
  58. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;5:235–240
  59. Dhoble A, Khasnis A, Olomu A, et al. Cardiac amyloidosis treated with an implantable cardioverter defibrillator and subcutaneous array lead system: report of a case and literature review. Clin Cardiol. 2009;
  60. Eder L, Zisman D, Wolf R, et al. Pulmonary hypertension and amyloidosis-an uncommon association: a case report and review of the literature. J Gen Intern Med. 2007;22:416–419
  61. Comenzo RL, Vosburgh E, Falk RH, et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998;91:3662–3670
  62. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med. 2004;140:85–93
  63. Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007;357:1083–1093
  64. Palladini G, Russo P, Lavatelli F, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol. 2009;88:347–350
  65. Hosenpud JD, DeMarco T, Frazier OH, et al. Progression of systemic disease and reduced long-term survival in patients with cardiac amyloidosis undergoing heart transplantation. Follow-up results of a multicenter survey. Circulation. 1991;84(5 Suppl.):III338–43
  66. Hosenpud JD, Uretsky BF, Griffith BP, et al. Successful intermediate-term outcome for patients with cardiac amyloidosis undergoing heart transplantation: results of a multicenter survey. J Heart Transplant. 1990;9:346–350
  67. Dubrey S, Simms RW, Skinner M, et al. Recurrence of primary (AL) amyloidosis in a transplanted heart with four-year survival. Am J Cardiol. 1995;76:739–741
  68. Dubrey S, Burke M, Hawkins P, et al. Cardiac transplantation for amyloid heart disease: The United Kingdom experience. J Heart Lung Transplant. 2004;23:1142–1153
  69. Kpodonu J, Massad MG, Caines A, et al. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant. 2005;24:1763–1765
  70. Roig E, Almenar L, Gonzalez-Vilchez F, Rabago G, Delgado J, Gomez-Bueno M, et al. Outcomes of heart transplantation for cardiac amyloidosis: Subanalysis of the Spanish Registry for Heart Transplantation. Am J Transplant. 2009;
  71. Gillmore JD, Goodman HJ, Lachmann HJ, et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood. 2006;107:1227–1229
  72. Maurer MS, Raina A, Hesdorffer C, et al. Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation. 2007;83:539–545
  73. Chen JM, Russo MJ, Hammond KM, et al. Alternate waiting list strategies for heart transplantation maximize donor organ utilization. Ann Thorac Surg. 2005;80:224–228
  74. Mignot A, Varnous S, Redonnet M, et al. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis. 2008;101:523–532
  75. Sack FU, Kristen A, Goldschmidt H, et al. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J Cardiothorac Surg. 2008;33:257–262
  76. Kristen AV, Sack FU, Schonland SO, et al. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Eur J Heart Fail. 2009;11:1014–1020
  77. Mignot A, Bridoux F, Thierry A, et al. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis. Haematologica. 2008;93:e32–e35
  78. Audard V, Matignon M, Weiss L, et al. Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic Al amyloidosis. Am J Transplant. 2009;9:236–240
  79. Hess EP, White RD. Out-of-hospital cardiac arrest in patients with cardiac amyloidosis: presenting rhythms, management and outcomes in four patients. Resuscitation. 2004;60:105–111
  80. Connors LH, Lim A, Prokaeva T, et al. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10:160–184
  81. Westermark P, Sletten K, Johansson B, et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci U S A. 1990;87:2843–2845
  82. Yazaki M, Tokuda T, Nakamura A, et al. Cardiac amyloid in patients with familial amyloid polyneuropathy consists of abundant wild-type transthyretin. Biochem Biophys Res Commun. 2000;274:702–706
  83. Jacobson DR, Pastore RD, Yaghoubian R, et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in Black Americans. N Engl J Med. 1997;336:466–473
  84. Connors LH, Prokaeva T, Lim A, et al. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158:607–614
  85. Gillmore JD, Booth DR, Pepys MB, et al. Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man. Heart. 1999;e2:82
  86. Falk RH. The neglected entity of familial cardiac amyloidosis in African Americans. Ethn Dis. 2002;12:141–143
  87. Eriksson M, Schonland S, Yumlu S, et al. Hereditary apolipoprotein AI-associated amyloidosis in surgical pathology specimens: identification of three novel mutations in the APOA1 gene. J Mol Diagn. 2009;11:257–262
  88. Gillmore JD, Lachmann HJ, Rowczenio D, et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol. 2009;20:444–451
  89. Mourad G, Delabre JP, Garrigue V. Cardiac amyloidosis with the E526V mutation of the fibrinogen A alpha-chain. N Engl J Med. 2008;359:2847–2848
  90. Gillmore JD, Stangou AJ, Tennent GA, et al. Clinical and biochemical outcome of hepatorenal transplantation for hereditary systemic amyloidosis associated with apolipoprotein AI Gly26Arg. Transplantation. 2001;71:986–992
  91. Kiuru S, Matikainen E, Kupari M, et al. Autonomic nervous system and cardiac involvement in familial amyloidosis, Finnish type (FAF). J Neurol Sci. 1994;126:40–48
  92. Chastan N, Baert-Desurmont S, Saugier-Veber P, et al. Cardiac conduction alterations in a French family with amyloidosis of the Finnish type with the p.Asp187Tyr mutation in the GSN gene. Muscle Nerve. 2006;33:113–119
  93. Ng B, Connors LH, Davidoff R, et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med. 2005;165:1425–1429
  94. Dubrey SW, Cha K, Skinner M, et al. Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcome. Heart. 1997;78:74–82
  95. Zeldenrust S, Gertz M, Uemichi T, et al. Orthotopic liver transplantation for hereditary fibrinogen amyloidosis. Transplantation. 2003;75:560–561
  96. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341:1113–1116
  97. Dubrey SW, Davidoff R, Skinner M, et al. Progression of ventricular wall thickening after liver transplantation for familial amyloidosis. Transplantation. 1997;64:74–80
  98. Stangou AJ, Hawkins PN, Heaton ND, et al. Progressive cardiac amyloidosis following liver transplantation for familial amyloid polyneuropathy: implications for amyloid fibrillogenesis. Transplantation. 1998;66:229–233
  99. Pomfret EA, Lewis WD, Jenkins RL, et al. Effect of orthotopic liver transplantation on the progression of familial amyloidotic polyneuropathy. Transplantation. 1998;65:918–925
  100. Yazaki M, Mitsuhashi S, Tokuda T, et al. Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant. 2007;7:235–242
  101. Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid. 2007;14:277–282
  102. Ihse E, Stangou AJ, Heaton ND, et al. Proportion between wild-type and mutant protein in truncated compared to full-length ATTR: an analysis on transplanted transthyretin T60A amyloidosis patients. Biochem Biophys Res Commun. 2009;379:846–850
  103. Arpesella G, Chiappini B, Marinelli G, et al. Combined heart and liver transplantation for familial amyloidotic polyneuropathy. J Thorac Cardiovasc Surg. 2003;125:1165–1166
  104. Grazi GL, Cescon M, Salvi F, Ercolani G, Ravaioli M, Arpesella G, et al. Combined heart and liver transplantation for familial amyloidotic neuropathy: considerations from the hepatic point of view. Liver Transpl. 2003;9986–9992
  105. Dubrey SW, Burke MM, Hawkins PN, et al. Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant. 2004;23:1142–1153
  106. Inomata Y, Zeledon ME, Asonuma K, et al. Whole-liver graft without the retrohepatic inferior vena cava for sequential (domino) living donor liver transplantation. Am J Transplant. 2007;7:1629–1632
  107. Singer R, Mehrabi A, Schemmer P, et al. Indications for liver transplantation in patients with amyloidosis: a single-center experience with 11 cases. Transplantation. 2005;80(1 Suppl.):S156–S159
  108. Goto T, Yamashita T, Ueda M, et al. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant. 2006;6:2512–2515
  109. Stangou AJ, Heaton ND, Hawkins PN. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med. 2005;352:2356
  110. Bergstrom J, Gustavsson A, Hellman U, et al. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol. 2005;206:224–232
  111. Sharma PP, Payvar S, Litovsky SH. Histomorphometric analysis of intramyocardial vessels in primary and senile amyloidosis: epicardium versus endocardium. Cardiovasc Pathol. 2008;17:65–71
  112. Kyle RA, Spittell PC, Gertz MA, et al. The premortem recognition of systemic senile amyloidosis with cardiac involvement. Am J Med. 1996;101:395–400
  113. Rapezzi C, Merlini G, Quarta CC, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation. 2009;120:1203–1212
  114. Fuchs U, Zittermann A, Suhr O, et al. Heart transplantation in a 68-year-old patient with senile systemic amyloidosis. Am J Transplant. 2005;5:1159–1162
  115. Cardoso I, Merlini G, Saraiva MJ. 4′-Iodo-4′-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 2003;17:803–809
  116. Palha JA, Ballinari D, Amboldi N, et al. 4′-Iodo-4′-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid. Am J Pathol. 2000;156:1919–1925
  117. Peterson SA, Klabunde T, Lashuel HA, et al. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc Natl Acad Sci U S A. 1998;95:12956–12960
  118. Saraiva MJ. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat. 2001;17:493–503
  119. Oza VB, Smith C, Raman P, et al. Synthesis, structure, and activity of diclofenac analogues as transthyretin amyloid fibril formation inhibitors. J Med Chem. 2002;45:321–332
  120. Almeida MR, Gales L, Damas AM, et al. Small transthyretin (TTR) ligands as possible therapeutic agents in TTR amyloidoses. Curr Drug Targets CNS Neurol Disord. 2005;4:587–596
  121. Gillmore JD, Hawkins PN. Drug insight: emerging therapies for amyloidosis. Nat Clin Pract Nephrol. 2006;2:263–270
  122. Coelho T, Maia M, Martins da Silva A, et al. A landmark clinical trial of a novel small molecule transthyretin (TTR) stabilizer, Fx-1006A, in patients with TTR amyloid polyneuropathy: a phase II/III, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(Suppl. 3):A205
  123. Coelho T, Waddington-Cruz M, Plante-Bordeneuve V, et al. Correlation of clinical outcomes and disease burden in patients with transthyretin (TTR) amyloid polyneuropathy: study Fx-005, a landmark clinical trail of Fx-1006A, a novel small molecule TTR stabilizer. J. Neurol. 2008;255(Suppl. 1):78
  124. Sekijima Y, Dendle MA, Kelly JW. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid. 2006;13:236–249
  125. Tojo K, Sekijima Y, Kelly JW, et al. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res. 2006;
  126. Mairal T, Nieto J, Pinto M, et al. Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors. PLoS ONE. 2009;4:e4124
  127. Miller SR, Sekijima Y, Kelly JW. Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest. 2004;84:545–552
  128. Miroy GJ, Lai Z, Lashuel HA, et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc Natl Acad Sci U S A. 1996;93:15051–15056
  129. Dubrey SW, Cha K, Simms RW, et al. Electrocardiography and Doppler echocardiography in secondary (AA) amyloidosis. Am J Cardiol. 1996;77:313–315
  130. Kaye GC, Butler MG, d'Ardenne AJ, et al. Isolated atrial amyloid contains atrial natriuretic peptide: a report of six cases. Br Heart J. 1986;56:317–320
  131. Kawamura S, Takahashi M, Ishihara T, et al. Incidence and distribution of isolated atrial amyloid: histologic and immunohistochemical studies of 100 aging hearts. Pathol Int. 1995;45:335–342
  132. Steiner I. The prevalence of isolated atrial amyloid. J Pathol. 1987;153:395–398
  133. Ariyarajah V, Steiner I, Hajkova P, et al. The association of atrial tachyarrhythmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens. Cardiology. 2009;113:132–137
  134. Goette A, Rocken C. Atrial amyloidosis and atrial fibrillation: a gender-dependent “arrhythmogenic substrate”?. Eur Heart J. 2004;25:1185–1186
  135. Leone O, Boriani G, Chiappini B, et al. Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J. 2004;25:1237–1241
  136. Steiner I, Hajkova P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol. 2006;15:287–290
  137. Rocken C, Peters B, Juenemann G, et al. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 2002;106:2091–2097

 Statement of Conflict of Interest: see page 358.

PII: S0033-0620(09)00097-8

doi: 10.1016/j.pcad.2009.11.007

Progress in Cardiovascular Diseases
Volume 52, Issue 4 , Pages 347-361 , January 2010

Article Tools

* Image Usage & Resolution